ERNA_OUT_1 [2025-04-03 18:59:58 -0400] 2764 Bytes | 726 tokens | Cum: 726 tkns (9.07% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 6:59:57 PM on Thu Apr 03, 2025 -0400, and I'm firing up the spotlight on Ernexa Therapeutics (ERNA), moving from 0.191 to 0.24. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Ernexa Therapeutics (ERNA)
IPO: 2021-03-26 (4 Years Ago)
Market Cap: $9,456,332
Shares Outstanding: 52,250,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.

Here's the first list of news for Ernexa Therapeutics:

C1 - Today 08:55AM - Ernexa Therapeutics Closes New Funding Round
C2 - Mar-25-25 08:30AM - Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
C3 - Feb-26-25 08:30AM - Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
C4 - Jan-29-25 08:46AM - Eterna appoints Zeldis, Sather to scientific advisory board
C5 - Jan-28-25 08:30AM - Eterna Therapeutics Announces Expansion of Scientific Advisory Board
C6 - Jan-14-25 08:30AM - Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
C7 - Jan-09-25 07:30AM - Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
C8 - Dec-03-24 08:30AM - Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Ernexa Therapeutics (ERNA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ERNA_OUT_3 [2025-04-03 19:00:03 -0400] 1100 Bytes | 303 tokens | Cum: 1031 tkns (12.89% of 8k)
==========================================================================

Showing C1 (chunk 1 of 5): C1:
**Ernexa Therapeutics Closes New Funding Round**
Date: Today 08:55AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/03/3055191/0/en/Ernexa-Therapeutics-Closes-New-Funding-Round.html

April 03, 2025 08:55 ET| Source:Ernexa Therapeutics Inc.Ernexa Therapeutics Inc.

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) --Ernexa Therapeutics(Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securities purchase agreement with accredited investors for the private placement of approximately 69.3 million shares of common stock (or pre-funded warrants to purchase shares of common stock), at a purchase price of $0.1046 per share for an aggregate purchase price of approximately $7,250,000, assuming the Company receives stockholder approval.

“These are very e

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ERNA_OUT_5 [2025-04-03 19:00:04 -0400] 962 Bytes | 289 tokens | Cum: 1412 tkns (17.65% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T21:05:48Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Aldeyra Therapeutics (NASDAQ:ALDX)...
A2 - 2025-04-03T13:06:10Z - Ernexa Therapeutics Closes New Funding Round...
A3 - 2025-04-03T13:09:53Z - Ernexa Therapeutics Closes New Funding Round | Taiwan News | Apr. 3, 2025 20:55...
A4 - 2025-03-25T12:56:25Z - Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Ca...
A5 - 2025-03-25T12:47:47Z - Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Ca...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ERNA_OUT_7 [2025-04-03 19:00:10 -0400] 1098 Bytes | 335 tokens | Cum: 1749 tkns (21.86% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Thursday's After-Market Session - Aldeyra Therapeutics (NASDAQ:ALDX), Aditxt (NASDAQ:ADTX)**Date: 2025-04-03Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44637576/12-health-care-stocks-moving-in-thursdays-after-market-sessionGainers Impact BioMedical IBO shares increased by 94.6% to $0.9 during Thursday's after-market session. The company's market cap stands at $10.3 million. Entero Therapeutics ENTO shares moved upwards by 85.35% to $0.81. The market value of their outstanding shares is at $3.8 million. Sangamo Therapeutics SGMO shares rose 29.54% to $0.81. The market value of their outstanding shares is at $180.9 million. Aldeyra Therapeutics ALDX shares rose 15.19% to $1.63. The market value of their outstanding shares is at $97.0 million. Ernexa Therapeutics ERNA shares

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ERNA_OUT_9 [2025-04-03 19:00:11 -0400] 1188 Bytes | 354 tokens | Cum: 2268 tkns (28.35% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-05-10T12:00:00Z - Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
B2 - 2024-05-08T13:31:00Z - Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
B3 - 2024-02-20T13:30:00Z - Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
B4 - 2024-01-03T21:15:00Z - Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
B5 - 2023-12-20T21:15:00Z - Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
B6 - 2023-12-14T23:56:00Z - Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ERNA_OUT_11 [2025-04-03 19:00:15 -0400] 890 Bytes | 273 tokens | Cum: 2543 tkns (31.79% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/10/2879583/0/en/Eterna-Therapeutics-to-Present-at-the-ASGCT-27th-Annual-Meeting-on-Development-of-Beta-2-Microglobulin-Knockout-B2M-KO-iMSC-Line-with-Enhanced-Immunosuppressive-Activity-and-Stealt.htmlEterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ERNA_OUT_13 [2025-04-03 19:00:16 -0400] 1111 Bytes | 300 tokens | Cum: 2919 tkns (36.49% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-03 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 31, 2025, Ernexa Therapeutics Inc. (the Company) entered into a securities purchase agreement (the SPA) with certain accredited investors and a related registration rights agreement (the RRA). Pursuant to the SPA, t...

S2 - 2025-03-24 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 20, 2025, Eterna Therapeutics Inc. (the Company) issued a promissory note with an aggregate principal amount of $750,000 (the Promissory Note) to Charles Cherington. The Promissory Note accrues interest at a rate of...

S3 - 2025-03-12 10-K ITEM 7.

Mgts Discussion and Analysis of Fin Cond and Results of Oper ##TABLE_END

The following discussion should be read in conjunction with our CONS financial statements and the notes thereto included in Part II, Item 8 of this report. The fo...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ERNA_OUT_15 [2025-04-03 19:00:24 -0400] 1098 Bytes | 287 tokens | Cum: 3208 tkns (40.10% of 8k)
==========================================================================

Showing S1 (chunk 1 of 5): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On March 31, 2025, Ernexa Therapeutics Inc. (the Company) entered into a securities purchase agreement (the SPA) with certain accredited investors and a related registration rights agreement (the RRA). Pursuant to the SPA, the Company agreed to issue and sell to the investors, and the investors agreed to purchase from the Company, in a private placement, an aggregate of 58,262,918 shares of common stock at a purchase price of $0.1046 per share, and pre-funded warrants to purchase up to 11,048,736 shares of common stock, at a purchase price of $0.0996 per pre-funded warrant. The pre-funded warrants will be exercisable until exercised in full at a nominal exercise of $0.005 per share and may not be exercised to the extent such exercise would cause the holder to beneficially own more than 4.99% or 9.99%, as applicable, of the Compa

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ERNA_OUT_17 [2025-04-03 19:00:30 -0400] 1098 Bytes | 278 tokens | Cum: 3614 tkns (45.17% of 8k)
==========================================================================

Showing S1 (chunk 2 of 5): nys outstanding common stock.

Upon the initial closing of the SPA, on April 2, 2025, we sold to the investors an aggregate of 9,934,016 shares of common stock and 509,736 pre-funded warrants (such shares, including the shares underlying the pre-funded warrants equal to 19.99% of the Companys outstanding shares as of March 31, 2025. The second closing under the SPA, for the sale of 48,328,902 shares of common stock and 10,539,000 pre-funded warrants, will occur upon satisfaction or waiver of certain conditions, including without limitation, receipt of stockholder approval for such issuance as required under applicable Nasdaq listing rules. Pursuant to the SPA, we agreed to hold a shareholder meeting to seek such shareholder approval as soon as reasonably possible, and no later than June 30, 2025 (or July 30, 2025 if the Securities and Exchange Commission (the SEC) reviews the preliminar

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ERNA_OUT_19 [2025-04-03 19:00:41 -0400] 4993 Bytes | 1457 tokens | Cum: 5223 tkns (65.29% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 281,775 | Perf Month: -36.49% | Option/Short: No / Yes | Sales Y/Y TTM: 755.88% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 10.48M | Perf Quarter: -38.44% | Short Float: 1.87% | ROE: -2264.31% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.03 | Index: - | Short Ratio: 0.04 | ROI: -2045.68% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 29.78 | Market Cap: 9.46M | Short Interest: 0.37M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.03 | Shs Outstand: 51.39M | Beta: 5.70 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: -24.86% | Shs Float: 19.69M | Sales Q/Q: -94.12% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -40.12% | Inst Own: 1.90% | Sales past 5Y: 131.18% | Earnings: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -81.20% | Insider Own: 62.32% | Employees: 6 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: -20.02% | Insider Trans: 0.00% | Debt/Eq: 0.40 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Eterna Therapeutics Inc. (ERNA) by Luther Sanjeev (President & CEO) on 2025-02-07
- Stock Option (right to buy): 1123350 shares at $0 (D)

Inside Trans: Eterna Therapeutics Inc. (ERNA) by Cicala Peter (Unknown Title) on 2025-02-07
- Stock Option (Right to buy): 51485 shares at $0 (D)

Inside Trans: Eterna Therapeutics Inc. (ERNA) by Bristol James Arthur (Unknown Title) on 2025-02-07
- Stock Option (Right to buy): 72074 shares at $0 (D)

Inside Trans: Eterna Therapeutics Inc. (ERNA) by Gurrola Sandra M (Sr. VP of Finance) on 2025-02-07
- Stock Option (Right to buy): 150000 shares at $0 (D)

Inside Trans: Eterna Therapeutics Inc. (ERNA) by Wexler William A. (Unknown Title) on 2025-02-07
- Stock Option (right to buy): 124533 shares at $0 (D)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 582000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -44539000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.181
Average Volume: 183781.91
30-Day High: 0.2945
30-Day Low: 0.1744

[Detailed Financials: TTM 2024]
- Total Assets: $5,269,000.0
- Total Liabilities: $3,568,000.0
- Total Equity: $1,701,000.0
- Current Assets: $2,352,000.0
- Current Liabilities: $2,938,000.0

[Income Statement: TTM 2024]
- Revenue: $582,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.26

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-9,941,000.0

[Detailed Financials: FY 2024]
- Total Assets: $5,269,000.0
- Total Liabilities: $3,568,000.0
- Total Equity: $1,701,000.0
- Current Assets: $2,352,000.0
- Current Liabilities: $2,938,000.0

[Income Statement: FY 2024]
- Revenue: $582,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.26

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-9,941,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ERNA_OUT_21 [2025-04-03 19:00:44 -0400] 676 Bytes | 167 tokens | Cum: 5676 tkns (70.95% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ERNA_IN_23 [2025-04-03 19:00:44 -0400] 126 Bytes | 29 tokens | Cum: 5733 tkns (71.66% of 8k)
==========================================================================

====================================
[2025-04-03 19:00:44] # Analysis Completed
Elapsed Time: 46.94 seconds